{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:18:51Z","timestamp":1792729131586,"version":"4.5.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T00:00:00Z","timestamp":1636761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To investigate risk factors for orally administered 5-aminolevulinic acid (ALA)-induced hypotension for bladder cancer patients receiving photodynamic diagnosis (PDD)-assisted transurethral resection of bladder tumor (TURBT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients were categorized into two groups intraoperatively: a hypotensive group (minimum systolic blood pressure (SBP) \u226480\u2009mmHg) and a non-hypotensive group (minimum SBP &gt;\u200980\u2009mmHg). We examined differences between the hypotensive group and non-hypotensive groups to identify clinical risk of ALA-induced hypotension using multivariate logistic regression analysis and decision tree analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 282 cases with ALA-PDD-assisted TURBT from three institutions who were screened, 245 patients were included in the final analysis. In total, 156 patients (63.7%) showed any grade of hypotension during ALA-PDD-assisted TURBT. General anesthesia and spinal anesthesia were induced intraoperatively in 113 patients (46.1%) and 132 patients (53.9%), respectively. Median SBP at baseline (before taking ALA) and at the beginning of anesthesia was 127\u2009mmHg (range, 69\u2013186\u2009mmHg) and 124\u2009mmHg (range, 69\u2013186\u2009mmHg), respectively. Median minimum SBP during ALA-PDD-assisted TURBT was 75\u2009mmHg (range, 43\u2013140\u2009mmHg). Multivariate logistic regression analysis revealed that history of hypertension (odds ratio (OR) 7.568,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) and general anesthesia (OR 14.435, p\u2009&lt;\u20090.05) as significantly associated with an increased risk of hypotension incidence. Use of calcium antagonist showed significant negative associations with hypotension (OR 0.183,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). Decision tree analysis showed presence of general anesthesia, age\u2009\u2265\u200974\u2009years and American Society of Anesthesiologists physical status (ASA-PS) \u22652 as the most important discriminators.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>General anesthesia and hypertension were independent risk factors related to ALA-induced hypotension. In contrast, use of calcium antagonists was identified as a factor associated with reduced risk of ALA-induced hypotension.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-021-08976-1","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T18:02:28Z","timestamp":1636826548000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Identification of risk factors associated with oral 5-aminolevulinic acid-induced hypotension in photodynamic diagnosis for non-muscle invasive bladder cancer: a multicenter retrospective study"],"prefix":"10.1186","volume":"21","author":[{"given":"Hideo","family":"Fukuhara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshiro","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Hatakeyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Hyodo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyasu","family":"Okuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Mizokami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyasu","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Japan Urological Photodynamic Society","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,13]]},"reference":[{"issue":"5","key":"8976_CR1","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Conperat EM, Gontero P, Mostafid AH, Palou J, et al. European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)-2019 updte. Eur Urol. 2019;76(5):639\u201357. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.016.","journal-title":"Eur Urol"},{"issue":"5","key":"8976_CR2","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1016\/j.eururo.2013.03.059","volume":"64","author":"M Burger","year":"2013","unstructured":"Burger M, Grossman HB, Droller M, Droller M, Schmidbauer J, Hermann G, et al. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data. Eur Urol. 2013;64(5):846\u201354. https:\/\/doi.org\/10.1016\/j.eururo.2013.03.059.","journal-title":"Eur Urol"},{"issue":"4","key":"8976_CR3","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.eururo.2013.07.007","volume":"64","author":"M Rink","year":"2013","unstructured":"Rink M, Babjuk M, Catto JW, Jichlinski P, Shariat SH, Stenzel A, et al. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature. Eur Urol. 2013;64(4):624\u201338. https:\/\/doi.org\/10.1016\/j.eururo.2013.07.007.","journal-title":"Eur Urol"},{"issue":"6","key":"8976_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/cncr.10821","volume":"95","author":"D Zaak","year":"2002","unstructured":"Zaak D, Hungerhuber E, Schneede P, Stepp H, Frimberger D, Corvin S, et al. Role of 5-aminolevulinic acid in the detection of urothelial premalignant lesions. Cancer. 2002;95(6):234\u20138. https:\/\/doi.org\/10.1002\/cncr.10821.","journal-title":"Cancer."},{"issue":"2","key":"8976_CR5","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.urology.2006.10.015","volume":"69","author":"E Hungerhuber","year":"2007","unstructured":"Hungerhuber E, Stepp H, Kriegmair M, Stief C, Hofstetter A, Hartmann A, et al. Seven years\u2019 experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology. 2007;69(2):260\u20134. https:\/\/doi.org\/10.1016\/j.urology.2006.10.015.","journal-title":"Urology."},{"issue":"4","key":"8976_CR6","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.urology.2006.12.023","volume":"69","author":"S Denzinger","year":"2007","unstructured":"Denzinger S, Burger M, Walter B, Knuechel R, Roessler W, Wieland WF, et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology. 2007;69(4):675\u20139. https:\/\/doi.org\/10.1016\/j.urology.2006.12.023.","journal-title":"Urology."},{"issue":"8","key":"8976_CR7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/iju.13718","volume":"25","author":"Y Nakai","year":"2018","unstructured":"Nakai Y, Inoue K, Tsuzuki T, Shimamoto T, Shuin T, Nagao K, et al. Oral 5-aminolevulinic acid-mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: a multiple phase III study. Int J Urol. 2018;25(8):723\u20139. https:\/\/doi.org\/10.1111\/iju.13718.","journal-title":"Int J Urol"},{"issue":"2","key":"8976_CR8","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1124\/jpet.301.2.507","volume":"301","author":"JT Dalton","year":"2002","unstructured":"Dalton JT, Yates CR, Yin D, Marcus SA, Golub AL, Meyer MC. Clinical pharmacokinetics of 5-aminolevulinic acid in healthy volunteers and patients at high risk for recurrent bladder cancer. J Pharmacol Exp Ther. 2002;301(2):507\u201312. https:\/\/doi.org\/10.1124\/jpet.301.2.507.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"8976_CR9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pdpdt.2012.06.004","volume":"10","author":"J Bondad","year":"2013","unstructured":"Bondad J, Aboumarzouk OM, Moseley H, Kata SG. Oral 5-aminolevulinic acid induced photodynamic diagnostic Ureterorenoscopy--does the blood pressure require monitoring? Photodiagn Photodyn Ther. 2013;10(1):39\u201341. https:\/\/doi.org\/10.1016\/j.pdpdt.2012.06.004.","journal-title":"Photodiagn Photodyn Ther"},{"issue":"2","key":"8976_CR10","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/neuros\/nyx074","volume":"81","author":"W Stummer","year":"2017","unstructured":"Stummer W, Stepp H, Wiestler OD, Pichlmeier U. Randomized, prospective double-blinded study comparing 3 different doses of 5-Aminolevulinic acid for fluorescence-guided resections of malignant gliomas. Neurosurgery. 2017;81(2):230\u20139. https:\/\/doi.org\/10.1093\/neuros\/nyx074.","journal-title":"Neurosurgery."},{"issue":"1","key":"8976_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40981-019-0279-1","volume":"5","author":"T Yatabe","year":"2019","unstructured":"Yatabe T, Marie SL, Fukuhara H, Karashima T, Inoue K, Yokoyama M. 5-Aminolevulinic acid-induced severe hypotension during transurethral resection of a bladder tumor: a case report. J Anesth Clin Rep. 2019;5(1):58. https:\/\/doi.org\/10.1186\/s40981-019-0279-1.","journal-title":"J Anesth Clin Rep"},{"issue":"11","key":"8976_CR12","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/iju.14099","volume":"26","author":"T Nohara","year":"2019","unstructured":"Nohara T, Kato Y, Nakano T, Nakagawa T, Iwamoto H, Yaegashi H, et al. Intraoperative hypotension caused by oral administration of 5-aminolevulinic acid for photodynamic diagnosis in patients with bladder cancer. Int J Urol. 2019;26(11):1064\u20138. https:\/\/doi.org\/10.1111\/iju.14099.","journal-title":"Int J Urol"},{"key":"8976_CR13","first-page":"35","volume":"6","author":"T Yatabe","year":"2020","unstructured":"Yatabe T, Karashima T, Kume M, Kawanishi Y, Fukuhara H, Ueba T, et al. Identification of risk factors for post-induction hypotension in patients receiving 5-aminolevulinic acid: a single-center retrospective study. J Anesth Clin Rep. 2020;6:35.","journal-title":"J Anesth Clin Rep"},{"issue":"4","key":"8976_CR14","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.pdpdt.2013.03.007","volume":"10","author":"IW Chung","year":"2013","unstructured":"Chung IW, Eljamel S. Risk factors for developing oral 5-aminolevulinic acid-induced side effects in patients undergoing fluorescence guided resection. Photodiagn Photodyn Ther. 2013;10(4):362\u20137. https:\/\/doi.org\/10.1016\/j.pdpdt.2013.03.007.","journal-title":"Photodiagn Photodyn Ther"},{"issue":"4","key":"8976_CR15","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.bja.2018.04.036","volume":"121","author":"EM Wesselink","year":"2018","unstructured":"Wesselink EM, Kappen TH, Torn HM, Slooter AJC, van Klei WA. Intraoperative hypotension and the risk of postoperative adverse outcomes: a systematic review. Br J Anesth. 2018;121(4):706\u201321. https:\/\/doi.org\/10.1016\/j.bja.2018.04.036.","journal-title":"Br J Anesth"},{"issue":"3","key":"8976_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s002280000151","volume":"56","author":"G Popken","year":"2000","unstructured":"Popken G, Schultze-Seemann W, Seiler KU, Birkel M, Wetterauer U. Intravesical administration of 5-aminolevulinic acid (5-ALA). Safety and pharmacokinetics of 5-ALA and its metabolite protoporphyrin IX. Eur J Clin Pharmacol. 2000;56(3):241\u20136. https:\/\/doi.org\/10.1007\/s002280000151.","journal-title":"Eur J Clin Pharmacol"},{"issue":"5","key":"8976_CR17","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/gut.47.5.612","volume":"47","author":"R Ackroyd","year":"2000","unstructured":"Ackroyd R, Brown NJ, Davis MF, Stephenson TJ, Stoddard CJ, Reed MW. Photodynamic therapy for dysplastic Barrett\u2019s oesophagus: a prospective, double blind, randomised, placebo controlled trial. Gut. 2000;47(5):612\u20137. https:\/\/doi.org\/10.1136\/gut.47.5.612.","journal-title":"Gut."},{"issue":"4","key":"8976_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1054\/bjoc.2000.1300","volume":"83","author":"P Hinnen","year":"2000","unstructured":"Hinnen P, de Rooij FW, Terlouw EM, Terlouw EM, Edixhoven A, van Dekken H, et al. Porphyrin biosynthesis in human Barrett\u2019s oesophagus and adenocarcinoma after ingestion of 5-aminolaevulinic acid. Br J Cancer. 2000;83(4):539\u201343. https:\/\/doi.org\/10.1054\/bjoc.2000.1300.","journal-title":"Br J Cancer"},{"issue":"1","key":"8976_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1011-1344(98)00102-X","volume":"44","author":"J van den Boogert","year":"1998","unstructured":"van den Boogert J, van Hillegersberg R, de Rooij FW, de Bruin RW, Edixhoven-Bosdijk A, et al. 5-Aminolaevulinic acid-induced protoporphyrin IX accumulation in tissues: pharmacokinetics after oral or intravenous administration. J Photochem Photobiol B. 1998;44(1):29\u201338. https:\/\/doi.org\/10.1016\/S1011-1344(98)00102-X.","journal-title":"J Photochem Photobiol B"},{"issue":"1-2","key":"8976_CR20","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/S1011-1344(96)07348-4","volume":"37","author":"J Webber","year":"1997","unstructured":"Webber J, Kessel D, Fromm D. Plasma levels of protoporphyrin IX in humans after oral administration of 5-aminolevulinic acid. J Photochem Photobiol B. 1997;37(1-2):151\u20133. https:\/\/doi.org\/10.1016\/S1011-1344(96)07348-4.","journal-title":"J Photochem Photobiol B"},{"issue":"3","key":"8976_CR21","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1152\/ajplung.00482.2005","volume":"291","author":"CJ Mingone","year":"2006","unstructured":"Mingone CJ, Gupte SA, Chow JL, Ahmad M, Abraham NG, Wolin MS. Protoporphyrin IX generation from delta-aminolevulinic acid elicits pulmonary artery relaxation and soluble guanylate cyclase activation. AJP Lung Cell Mol Physiol. 2006;291(3):337\u201344. https:\/\/doi.org\/10.1152\/ajplung.00482.2005.","journal-title":"AJP Lung Cell Mol Physiol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08976-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-08976-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-08976-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T18:03:25Z","timestamp":1636826605000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-08976-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,13]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["8976"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-08976-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,13]]},"assertion":[{"value":"24 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This retrospective study was approved by the Ethics committee of Kochi Medical School (approved no. 31\u201388), and the requirement to obtain informed consent was waived for the retrospective study. Ethical approval from the local committee and the IDs are the following:Kanazawa university Ethics committee, ID: 3172\u20131.Saitama Medical University International Medical Center Ethics committee, ID: 19\u2013217.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors report the following financial interests;KI; Chugai Pharmaceutical Co., Ltd. \u2013 speaker fees.HM; Chugai Pharmaceutical Co., Ltd. \u2013 speaker fees.All other authors have nothing to disclose. Chugai Pharmaceutical Co., Ltd. played no role in the study design, data collection and analysis, decision to submit for publication, or preparation of the manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1223"}}